Search
Odesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigational[A222078] The chief surface target of EBOV particles is the GP<sub>1,2</sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.
Chloroquine
go.drugbank.com/drugs/DB00608ApprovedInvestigationalVet approved[A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine]. … [A192432] **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Products: CHLOROQUINE TABLETS 250 mg, CHLOROQUINE PHOSPHATE TABLETS 250 MGDonislecel
go.drugbank.com/drugs/DB17961Approved[L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and other pancreatic hormones from infused allogeneic islet cells to mimic endogenous glucose control … [L47166,L47196] The approval of donislecel was based on the safety and effectiveness evaluated in 2 clinical trials with 30 type 1 diabetic patients.
Genistein
go.drugbank.com/drugs/DB01645InvestigationalNatural sources of genistein include tofu, fava beans, soybeans, kudzu, and lupin. … It has shown to be effective in the treatment of common liver fluke, pork trematode and poultry cestode.
Mixtures: CALCIDAY G 1200 MG/800 IU/50 MG EFERVESAN TABLET, 45 ADET, CALCİDAY G 1000 MG/880 IU/50 MG EFERVESAN TABLET, 40 ADETCategories: Compounds used in a research, industrial, or household settingZanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigationalL10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. … [L39367] In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen
Products: BRUKINSA 80 mg capsulesDicloxacillin
go.drugbank.com/drugs/DB00485ApprovedInvestigationalVet approvedOne of the penicillins which is resistant to penicillinase.
Categories: combinations of penicillinsProducts: CLOXIL 500 MG, BAMAXIN 500 MGBremelanotide
go.drugbank.com/drugs/DB11653Approved[A179689] Bremelanotide was granted FDA approval on 21 June 2019.[L9635] … [A179686] The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449] … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart
Products: KERENDİA 10 MG FİLM KAPLI TABLET, 98 ADET, KERENDİA 20 MG FİLM KAPLI TABLET, 98 ADETEvinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigationalThe ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years. … Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.
Elotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. … Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks.